Targeting Neuronal Nitric Oxide Synthase (nNOS) for Melanoma Treatment

<p>Human cutaneous melanoma is the most aggressive form of skin cancer and the incidence rates have continued to increase over the years. Neuronal nitric oxide synthase (nNOS) produces nitric oxide (NO) has been found to be overexpressed in human melanoma and the expression of nNOS is induced by interferon-gamma (IFN-γ). In our studies, nNOS has been implicated in IFN-γ-stimulated melanoma progression and the inhibition of nNOS using novel inhibitors effectively inhibited IFN-γ-stimulated tumor growth in a xenograft mouse model. Programmed death-ligand 1 (PD-L1) is overexpressed in melanoma and plays an important role in suppressing the immune system ^12-14. Our <em>in vitro</em> and <em>in vivo </em>studies show that nNOS inhibitors exhibit potent cytotoxicity to melanoma cells and have immune modulating potential through the inhibition of PD-L1. In an immunocompetent allograft mouse model, daily intraperitoneal injections of nNOS inhibitors (HH044 or MAC-3-190) exhibited significant anti-melanoma activity and inhibited tumor growth, which was enhanced when combined with immune checkpoint inhibitors. The co-treatment with HH044 and anti-PD-1 immunotherapy significantly prolonged mouse survival compared to the control group. Of note, no significant distress, or alterations in appearance or behavior were noted during the study.</p> <p>Fluorescence-tagged confirmed that HH044 distributed to the tumor xenografts as detected by <em>in vivo </em>and<em> ex vivo </em>imaging. Consistently, further analysis demonstrated that nNOS inhibitor MAC-3-190 reached efficacious intratumor levels 30 minutes after a single <em>i.p.</em> injection and 24 hours after prolonged treatment. The utilization of targeting ligands was trialed to avoid possible adverse events and to improve the delivery of compounds to human melanoma cells. By screening a peptide library, we identified a peptide, KK-11, that binds specifically to and is internalized by melanoma cells. Our <em>in vivo</em> studies showed that a physical mixture of targeting peptide KK-11 with MAC-3-190 enhanced its anti-tumor activity in a human melanoma xenograft mouse model.</p> <p>Targeting peptides can allow for the utilization of a smaller quantity of the active drug and the sparing of normal tissues and organs from toxicity. Our strategy of developing specific nNOS targeted therapeutic interventions and melanoma targeted delivery to block disease progression will have both high impact and importance.</p>

Name thesis:degree_name

Doctor of Philosophy (PhD)

Level thesis:degree_level

Dissertation

Discipline thesis:degree_discipline

Pharmaceutical Sciences

Year dc:date.available

2022

Author dc:creator

• Tong, Shirley

Contributors dc:contributor

• Sun Yang
• Anand Ganesan
• Jennifer Totonchy
• Miao Zhang

• melanoma
• targeted therapy
• targeted delivery
• nNOS inhibitors
• peptide KK-11
• in vivo
• Biochemistry
• Immunotherapy
• Medical Pharmacology
• Medicinal Chemistry and Pharmaceutics
• Neoplasms
• Oncology
• Other Chemicals and Drugs
• Pharmaceutics and Drug Design
• Pharmacology
• Skin and Connective Tissue Diseases

Repository record dc:identifier

https://digitalcommons.chapman.edu/pharmaceutical_sciences_dissertations/17

OAI identifier oai:identifier

oai:digitalcommons.chapman.edu:pharmaceutical_sciences_dissertations-1017